Effect of a selective <scp>SGLT</scp>2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats

  • Asadur Rahman
    Department of Pharmacology Faculty of Medicine Kagawa University Kagawa Japan
  • Yoshihide Fujisawa
    Life Science Research Center Faculty of Medicine Kagawa University Kagawa Japan
  • Daisuke Nakano
    Department of Pharmacology Faculty of Medicine Kagawa University Kagawa Japan
  • Hirofumi Hitomi
    Department of Pharmacology Faculty of Medicine Kagawa University Kagawa Japan
  • Akira Nishiyama
    Department of Pharmacology Faculty of Medicine Kagawa University Kagawa Japan

この論文をさがす

説明

<jats:title>Summary</jats:title><jats:p>Metabolic syndrome is often associated with disruption of circadian rhythm of systemic haemodynamics and cardiovascular disease. Experiments were conducted to investigate the effects of luseogliflozin, a selective <jats:styled-content style="fixed-case">SGLT</jats:styled-content>2 inhibitor, on circadian rhythm of sympathetic nervous function and locomotor activity (<jats:styled-content style="fixed-case">LA</jats:styled-content>) in metabolic syndrome rats. The difference in the low frequency component of systolic blood pressure between the dark and light period significantly increased in the luseogliflozin‐treated <jats:styled-content style="fixed-case">SHR</jats:styled-content>cp. <jats:styled-content style="fixed-case">LA</jats:styled-content> also increased in the dark period compared with the light period following luseogliflozin treatment. These data suggest that circadian rhythm of sympathetic nervous function and <jats:styled-content style="fixed-case">LA</jats:styled-content> is improved by luseogliflozin in metabolic syndrome rats, which may contribute to <jats:styled-content style="fixed-case">SGLT</jats:styled-content>2 inhibitor‐induced improvement of cardiovascular outcomes.</jats:p>

収録刊行物

被引用文献 (9)*注記

もっと見る

参考文献 (25)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ